RAS Inhibitor Resistance in PDAC at AACR 2025 At the AACR 2025 Annual Meeting in Chicago, Dr. Andrew Aguirre from…
Browsing: AACR
A New Approach to MMRd/MSI-H Tumors At the AACR Annual Meeting 2025 in Chicago, Dr. Andrea Cercek presented compelling data…
Published on May 3, 2025 Antibody-drug conjugates (ADCs) have revolutionized oncology, offering targeted cancer treatments that minimize harm to healthy…
Introduction Zongertinib (BI 1810631) has shown promising results in treating HER2-mutant non-small cell lung cancer (NSCLC), with a 71% response…
Introduction The KEYNOTE-689 clinical trial has provided a significant update on pembrolizumab’s role in treating resectable locally advanced head and…
Date: March 11, 2025 Renowned Cancer Researcher Honored in 2025 The American Association for Cancer Research (AACR) and the Pezcoller…
LOS ANGELES AACR IO 2025 At a recent oncology session from AACR Immunotherapy 2025, Melissa G. Lechner, MD, PhD, presented…
Posted on February 28, 2025 | Jose Ramon Conejo-Garcia,MD, PHD – Duke Cancer Institute Cancer immunotherapy has long been dominated…
February 26, 2025 | By Michael Karin, Phd Liver cancer, specifically hepatocellular carcinoma (HCC), is on the rise—and a sneaky…
Los Angeles, February 2025 The AACR IO 2025 conference in Los Angeles has become a beacon for cutting-edge cancer research.…
Los Angeles, February 2025 – The inaugural AACR IO Conference kicked off with an electrifying start, bringing together the world’s…